

Panion's emission is finalized and the dog safety study is progressing well

Panion's shares emission that was running from 16-30 May and raised appr. 5.2 MSEK before emission costs, has now been completed and all payments processed.

The CEO and three members of the management had signed up for buying shares in Panion in this emission, and this was finalized well for CEO Anja Holm and board member Lars Friis Mikkelsen. However, for board member Dede Willis and Director of Business development Carlos N Velez, the American banks could not handle the requested transactions via Spotlight Stock Market, and these two subscriptions had to be cancelled. Instead the shares are sold to Swedish investors.

"This is very unfortunate, because we certainly would have liked to include these two leading profiles on the list of shareholders", says CEO Anja Holm, "but we appreciate all the effort that was put into finding solutions for a very complex situation."

Panion is currently running a safety study in dogs with the innovative product candidate GCO1-canine in cooperation with the University of Copenhagen under the lead of associate professor David Woldbye, Department of Neuroscience.

"The study is progressing well, and the animal phase is so far without negative or unforeseen events for all dogs in the study. We are very pleased with the development and look forward to



Anja Holm, CEO, Panion Animal Health AB

finalizing the animal phase according to plan, so we can report the results to the market as soon as possible" says CEO Anja Holm. "The coming steps in the development plan is a pilot clinical study in client-owned dogs, which have drug-resistant epilepsy".

For additional information, contact:

Anja E. H. Holm, CEO | +45-22 94 66 00
anja.holm@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at Spotlight Stock Market.

Panion Animal Health AB

info@panion-animalhealth.com

[linkedin.com/company/panion-animalhealth](https://www.linkedin.com/company/panion-animalhealth) 

twitter.com/panionanihealth 

panion-animalhealth.com/newsletter 

panion-animalhealth.com 